Deciphera Pharmaceuticals Inc.
$21.9M 3,335 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Aadi Bioscience, Inc.
Aadi Bioscience, Inc. reported $21,452,726.51 across General Payments, Research, and Ownership to 436 physicians and teaching hospitals across 1,601 transactions.
- $21.5M
- All-tracks total
- 1,601
- Transactions
- 436
- Recipients
- −$100.1K
- General Payments vs PY2023
Aadi Bioscience, Inc. reported $21,452,726.51 across all CMS Open Payments tracks (General + Research + Ownership) to 436 physicians and teaching hospitals in Program Year 2024 - ranking #88 of 1,925 reporting manufacturers (0.2% of the all-tracks industry total); General Payments alone were $255,357.96, averaging $49.2K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer aadi-bioscience-inc Aadi Bioscience, Inc.
$21.5M · #88/1,925 · 0.2% industry · PY2024
- TOT $21.5M
- RANK #88
- SHARE 0.2%
- TXN 1,601
- RCP 436
- CAT 5
- GEN $255.4K
- ΔGEN −$100.1K
- TOP1 31.3%
- PY 2024
Volume peers
Nearest volume peer: Deciphera Pharmaceuticals Inc. ($21.9M)
Aadi Bioscience, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Aadi Bioscience, Inc.'s CMS-reported General Payments decreased by $100.1K (−28.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: AADI BIOSCIENCE, INC.PY2023: AADI BIOSCIENCE, INC.PY2024: Aadi Bioscience, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $355,472.31
- PY2024
- $255,357.96
What the Data Shows for Aadi Bioscience, Inc.
$21,452,726.51: that is what Aadi Bioscience, Inc. reported in payments to 436 physicians and teaching hospitals during Program Year 2024, spread across 1,601 transactions ($13.4K per transaction, $49.2K per recipient). The company sits at rank #88 of 1,925, representing 0.2% of all industry payments reported nationwide for the year.
42 transactions worth $127.1K make "Consulting Fee" the top general-payment category in the 5-category breakdown below, 49.8% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Aadi Bioscience, Inc.'s 5-category general-payment breakdown at $127.1K, 49.8% of the reported total.
Aadi Bioscience, Inc. reports 5 general-payment categories - the top three are Consulting Fee (49.8%), Honoraria (35.1%), and Food and Beverage (9.7%). The remaining 2 categories make up 5.4% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Aadi Bioscience, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $127.1K | 42 | 49.8% |
| Honoraria | $89.8K | 19 | 35.1% |
| Food and Beverage | $24.8K | 365 | 9.7% |
| Compensation for Services Other Than Consulting | $13.6K | 9 | 5.3% |
| Education | $99.99 | 1 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $151,334.66 (59.3%) of $255,357.96 in this company's General Payments records across 286 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Aadi Bioscience, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Caley Castelein
$80,000.00 across 4 reported transactions
- 2
George D Demetri
$50,000.00 across 5 reported transactions
- 3
William D Tap
$7,965.00 across 2 reported transactions
- 4
Arun Sayram Singh
$7,174.66 across 4 reported transactions
- 5
Martee L Hensley
$6,195.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Aadi Bioscience, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Aadi Bioscience, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Aadi Bioscience, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Sage Therapeutics, Inc.
$20.9M 10,198 recipients
Compare payment profiles
Ucb SA
$20.6M 617 recipients
Compare payment profiles
Alphatec Spine, Inc
$22.3M 6,836 recipients
Compare payment profiles
Ge Healthcare
$20.5M 6,646 recipients
Compare payment profiles
Galderma Laboratories, L.P.
$20.5M 59,761 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.